Eyebright Medical has been awarded the highest rating of Level A in the Shanghai Stock Exchange's evaluation of information disclosure for the 2023 to 2024 period. This recognition marks the company's second consecutive A rating and highlights its commitment to excellence in transparency and regulatory governance, reflecting strong investor relations management and operational integrity.

The company prioritizes corporate governance and information disclosure, adhering to principles of transparency, accuracy, completeness, and timeliness. Eyebright Medical voluntarily shares product information through innovative approval channels and publishes social responsibility reports and visualized financial statements on its official website and WeChat platform, ensuring investors have a clear understanding of its performance.

Through various communication channels, including "Shanghai Stock Exchange e-Interaction," investor hotlines, and shareholder meetings, Eyebright Medical has built strong connections with a diverse investor base, maintaining a 100% response rate on the e-Interaction platform. In the first half of 2024, the company invited retail investors to participate in online and offline sessions, allowing for direct engagement with the Chairman and core management team, which received positive feedback.

Looking ahead, Eyebright Medical will continue to enhance its corporate governance and regulatory practices, implement the "2024 Quality Improvement, Efficiency Enhancement, and Return Action Plan," and improve its information disclosure standards. The company aims to strengthen investor communication and solidify its position as a leading publicly listed company with robust competitiveness and significant market influence.